Phytopharm fund raising collapses as partner threatens to quit deal
Tuesday 01 March 2005
Phytopharm's £24M fund raising has collapsed after a Japanese partner said it may pull out of an agreement to develop the company's most advanced drug.
Yamanouchi, which has rights to Phytopharm's potential treatment for Alzheimer's, said it is weeding out its portfolio of drug projects after a merger.
The UK biotech, which tries to develop drugs from plants, was notified of Yamanouchi's intentions shortly after a shareholder meeting which approved the placing and open offer at 180p a share - at "10.28am, just as the directors were driving out of the car park", according to Richard Dixey, the chief executive.
The stock slumped 20 per cent to 161.5p yesterday.
The placing had been intended to allow Phytopharm to negotiate further licensing deals for the Alzheimer's drug - called Cogane and developed from plants given to elderly people in the Far East - without potential partners being able to screw the company down on price. Without the funds, Phytopharm will have cash to last only an estimated 12 months and will no longer be negotiating from a position of financial strength.
Mr Dixey said "the wolf is not at the door" but the company is expected to reverse plans for speeding up the development of a motor neurone drug. He added: "It is about the only thing that can destroy a placing, a material event in the six hours between an extraordinary general meeting and the offering of the shares."
An aggrieved Mr Dixey said the decision to pull the fund raising had to be made on a "technicality" since the prospectus on which the shares were sold reflected Phytopharm's confidence that the Yamanouchi deal would endure. He said: "This is a reflection of labyrinthine complexity of raising money in the UK, and of having to meet these incredible set of rules. Effectively, you must have a business that is pickled in aspic for 28 days, since you need a prospectus that is accurate in every last detail for that length of time."
Pfizer canned development work on a potential obesity drug which Phytopharm had developed from a desert cactus. The technology has since been licensed by Unilever for potential use in diet foods.
- 1 Autistic teenager beaten up by bullies makes them watch 20-minute video about autism
- 2 Nick Kyrgios calls former Olympian Dawn Fraser a 'blatant racist' after she tells Wimbledon star to 'go back where their parents came from'
- 3 World learns of app that shows you who unfriended you on Facebook, app promptly crashes
- 4 Chris Moyles reportedly set to make radio comeback with new breakfast show on XFM
- 5 The Greece debt crisis explained in less than 100 words
Florida man sentenced to two-and-a-half years for having sex on the beach in front of a child
Autistic teenager beaten up by bullies makes them watch 20-minute video about autism
Man who was struck and killed by lightning in Brecon Beacons 'was carrying a selfie stick'
Greece debt crisis as it happened: EU chiefs at loggerheads hours before Alexis Tsipras’s last ditch deal proposals
Florida teacher sentenced to 22 years in prison for sexually abusing three pupils
More Britons believe that multiculturalism makes the country worse - not better, says poll
Osborne to cap family benefits at £23,000 – announced ahead of his post-election Budget
Nathan Collier: Montana man inspired by same-sex marriage ruling requests right to wed two wives
Forget little green men – aliens will look like humans, says Cambridge University evolution expert
Girl, 7, stares down hate preacher at Ohio festival with pro-LGBT rainbow flag gesture
Sickness and disability benefits could be reduced by £30 a week as part of £12bn welfare cuts
iJobs Money & Business
£40000 - £95000 per annum: Recruitment Genius: This is an exciting opportunity...
competitive: SThree: Are you passionate about sales?Do you have a keen interes...
£17000 - £30000 per annum: Recruitment Genius: This is an exciting opportunity...
£15000 - £17000 per annum: Recruitment Genius: This company offers a range of ...